Login / Signup

Using a Recently Approved Tumor Mutational Burden Biomarker to Stratify Patients for Immunotherapy May Introduce a Sex Bias.

Neelam SinhaSanju SinhaKuoyuan ChengSanna MadanAyelet ErezBríd M RyanAlejandro A SchäfferKenneth D AldapeEytan Ruppin
Published in: JCO precision oncology (2022)
Keyphrases
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • chronic kidney disease
  • peritoneal dialysis
  • risk factors
  • patient reported